Why is Windlas Biotech falling/rising?

As of 24-Sep, Windlas Biotech Ltd is currently priced at 931.00, reflecting a decrease of 10.25, or 1.09%. The stock has been underperforming, having fallen consecutively for the last three days, resulting in a total decline of 3.31% during this period. Additionally, it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. The delivery volume has also decreased significantly, down 49.62% from the 5-day average, suggesting reduced investor participation. Despite a strong performance in the previous year with a return of 10.75%, the stock has seen a decline of 9.91% year-to-date, contrasting with the overall market's positive performance.
In the broader market context, Windlas Biotech's short-term performance has been notably weaker than the benchmark, with a 1-week return of -4.44% compared to the Sensex's -1.18%. This underperformance is compounded by the stock's premium valuation relative to its peers, despite its low debt-to-equity ratio and consistent returns over the past three years. While the company has reported positive financial results, including record net sales and profit before tax, the high PEG ratio of 3.6 indicates that the stock may be overvalued, contributing to investor caution and the recent price decline.